Protega Pharmaceuticals Inc.

FDA Approves Protega's Abuse-Deterrent ROXYBOND 10 mg for Severe Pain

• The FDA has approved Protega Pharmaceuticals' ROXYBOND 10 mg, an immediate-release oxycodone hydrochloride tablet, for managing severe pain where alternative treatments are inadequate. • ROXYBOND is the first and only FDA-approved abuse-deterrent immediate-release 10 mg oxycodone formulation expected to reduce abuse via intranasal and intravenous routes. • Formulated with SentryBond technology, ROXYBOND resists physical and chemical manipulation, making it more difficult to misuse while maintaining its intended release profile. • Protega plans to launch ROXYBOND 10 mg before the year's end, providing clinicians with an additional tool for mitigating the risk of opioid abuse in pain management.